JP2023506227A5 - - Google Patents

Info

Publication number
JP2023506227A5
JP2023506227A5 JP2022535965A JP2022535965A JP2023506227A5 JP 2023506227 A5 JP2023506227 A5 JP 2023506227A5 JP 2022535965 A JP2022535965 A JP 2022535965A JP 2022535965 A JP2022535965 A JP 2022535965A JP 2023506227 A5 JP2023506227 A5 JP 2023506227A5
Authority
JP
Japan
Prior art keywords
hours
minutes
days
ptpn2
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535965A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064709 external-priority patent/WO2021119554A1/en
Publication of JP2023506227A publication Critical patent/JP2023506227A/ja
Publication of JP2023506227A5 publication Critical patent/JP2023506227A5/ja
Priority to JP2026031034A priority Critical patent/JP2026094293A/ja
Pending legal-status Critical Current

Links

JP2022535965A 2019-12-12 2020-12-11 免疫活性を強化するための組成物および方法 Pending JP2023506227A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026031034A JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962947483P 2019-12-12 2019-12-12
US62/947,483 2019-12-12
PCT/US2020/064709 WO2021119554A1 (en) 2019-12-12 2020-12-11 Compositions and methods for potentiating immune activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026031034A Division JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2023506227A JP2023506227A (ja) 2023-02-15
JP2023506227A5 true JP2023506227A5 (cg-RX-API-DMAC7.html) 2023-12-18

Family

ID=76329104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022535965A Pending JP2023506227A (ja) 2019-12-12 2020-12-11 免疫活性を強化するための組成物および方法
JP2026031034A Pending JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026031034A Pending JP2026094293A (ja) 2019-12-12 2026-02-27 免疫活性を強化するための組成物および方法

Country Status (7)

Country Link
US (1) US12551555B2 (cg-RX-API-DMAC7.html)
EP (1) EP4073242A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023506227A (cg-RX-API-DMAC7.html)
CN (1) CN115103907A (cg-RX-API-DMAC7.html)
AU (1) AU2020401376A1 (cg-RX-API-DMAC7.html)
CA (1) CA3163012A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021119554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020401376A1 (en) 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
CN114668743B (zh) * 2021-08-04 2025-08-08 贵州医科大学附属医院 抑制黑色素瘤生长的纳米载药系统的制备方法及应用
CN116251099B (zh) * 2023-04-30 2026-07-24 兰州大学第二医院 含苯氧基乙酰肼化合物的胰腺癌jak2和stat3双靶向抑制剂及应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534637T1 (de) 2002-04-03 2011-12-15 Novartis Ag 5-substituierte 1,1-dioxo- 1,2,5 thiazolidin-3- onderivate als ptpase 1b hemmer
GB0225986D0 (en) 2002-11-07 2002-12-11 Astrazeneca Ab Chemical compounds
UA94724C2 (en) 2005-12-08 2011-06-10 Новартис Аг Thiadiazolidinone derivatives as antidiabetic agents
UA94921C2 (en) 2005-12-08 2011-06-25 Новартис Аг 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors
RU2008127253A (ru) 2005-12-08 2010-01-20 Новартис АГ (CH) 1,1,3-триоксо-1,2,5-тиадиазолидины и их применение в качестве ингибиторов птфаз
JP2009532379A (ja) 2006-03-31 2009-09-10 ノバルティス アクチエンゲゼルシャフト PTPaseのチアジアゾリジノン阻害剤
AR066820A1 (es) 2007-06-04 2009-09-16 Novartis Ag Compuestos de tiadiazolidin-3 ona
WO2009049098A2 (en) 2007-10-09 2009-04-16 Indiana University Research & Technology Corporation Materials and methods for regulating the activity of phosphatases
US9217012B2 (en) * 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
CN103561573A (zh) 2011-04-26 2014-02-05 印第安纳大学研究与技术公司 酪氨酸磷酸酶及其在调节参与结核分枝杆菌之病理学的酶的活性中的用途
CA2977839C (en) * 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
JP2017524348A (ja) * 2014-06-10 2017-08-31 モナッシュ ユニバーシティ 養子細胞移入のためのptpn2阻害を用いた白血球の産生方法
IL308735A (en) * 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
KR101826690B1 (ko) * 2015-11-06 2018-03-22 경북대학교 산학협력단 단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
US11311543B2 (en) 2016-05-27 2022-04-26 Yale University Compositions and methods for inhibiting PTPN22
WO2018227248A1 (en) * 2017-06-13 2018-12-20 Monash University Methods and compositions for the treatment of obesity
WO2019036815A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill University ENHANCEMENT OF CD8 + T LYMPHOCYTES FOR ADOPTIVE CELL THERAPY BY INHIBITING PTPN1 (PTP1B) AND PTPN2 (TC-PTP))
WO2019178422A1 (en) * 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
TWI888352B (zh) 2018-06-21 2025-07-01 美商嘉來克生命科學有限責任公司 蛋白質酪胺酸磷酸酯酶抑制劑及其使用方法
US20220081691A1 (en) * 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
KR102983496B1 (ko) 2019-03-14 2026-06-29 칼리코 라이프 사이언시스 엘엘씨 단백질 티로신 포스파타제 억제제 및 이의 사용 방법
AU2020395612A1 (en) 2019-12-04 2022-06-09 Monash University Methods of activating cytotoxic leukocytes using PTP1B and PTPN2 inhibitors
AU2020401376A1 (en) 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
MX2022007441A (es) 2019-12-18 2022-09-02 Calico Life Sciences Llc Inhibidores de proteína tirosina fosfatasa y sus métodos de uso.
CN116194453A (zh) 2019-12-20 2023-05-30 卡里科生命科学有限责任公司 蛋白质酪氨酸磷酸酶降解剂及其使用方法
CN113827727B (zh) 2020-06-24 2025-04-29 上海交通大学医学院附属瑞金医院 Ptpn2抑制剂在kras突变肿瘤中的应用
EP4211122A1 (en) 2020-09-11 2023-07-19 Calico Life Sciences LLC Protein tyrosine phosphatase inhibitors and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7857980B2 (ja) Cd19指向性キメラ抗原受容体および免疫療法におけるその使用
CN113286879B (zh) 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子
JP2024520676A5 (cg-RX-API-DMAC7.html)
JP2021525509A5 (cg-RX-API-DMAC7.html)
ES2988584T3 (es) Subconjunto de células NKT para persistencia y actividad terapéutica in vivo y propagación del mismo
IL273201B1 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
JP2019534246A5 (cg-RX-API-DMAC7.html)
CN110352068A (zh) 合成的免疫受体及其使用方法
EP3612222A1 (en) Compositions and methods for treating cancer
US20160015749A1 (en) Engager cells for immunotherapy
JP2019532997A5 (cg-RX-API-DMAC7.html)
JP2024509095A5 (cg-RX-API-DMAC7.html)
JP2020511462A5 (cg-RX-API-DMAC7.html)
WO2022199125A1 (zh) 一种自分泌IL-15与anti-PD1融合蛋白的免疫细胞
JP7186615B2 (ja) 遺伝子操作された薬物耐性t細胞およびその使用方法
JP2024519335A (ja) がん免疫療法のための投薬レジメン
US12178786B2 (en) Combination of cellular immunotherapy
JP2024531446A5 (cg-RX-API-DMAC7.html)
JP7541390B2 (ja) 免疫チェックポイント分子と結合可能な分子が融合したタンパク質およびその用途
CN112638428A (zh) 嵌合抗原受体肿瘤浸润淋巴细胞
JP2018526453A5 (cg-RX-API-DMAC7.html)
JP2025513607A (ja) Cd7遺伝子がノックアウトされた操作された免疫細胞及びその用途
GB2623191A (en) Engineered chimeric fusion protein compositions and methods of use thereof
TW201938196A (zh) 融合蛋白擴展
WO2020142780A1 (en) Car t cell methods and constructs